Is Ozempic Safe in the First Trimester?

The Short Answer: Ozempic Is Contraindicated in the First Trimester

Stop taking Ozempic as soon as you know you are pregnant, or ideally well before you try to conceive. The FDA prescribing label for semaglutide states plainly that Ozempic should be discontinued at least 2 months before a planned pregnancy because of the drug's long elimination half-life of approximately 7 days. That 2-month washout period covers roughly five half-lives, which is the standard pharmacokinetic threshold for meaningful drug clearance.

The "first trimester" framing matters because many pregnancies are unplanned. A woman taking Ozempic for type 2 diabetes or off-label for weight loss may not realize she is pregnant until week 6 or 7, well into organogenesis, the developmental window when fetal organs form and when teratogen exposure is most consequential. If that is your situation, stop the drug now and contact your prescriber or an OB-GYN the same day.

Why the First Trimester Is the Highest-Risk Window

Organogenesis runs from approximately day 18 to day 60 post-conception. The heart, neural tube, limb buds, and craniofacial structures all form during this window. Any drug with teratogenic potential in animal models carries its highest theoretical risk during this period, which maps almost exactly to the first trimester in human gestational weeks.

Semaglutide's 7-day half-life means that even if you took your last weekly injection the day you got a positive pregnancy test, meaningful drug concentrations persist for another 5 to 7 weeks, spanning a substantial portion of the first trimester.

What the Animal Data Actually Shows

Animal reproduction studies showed fetal harm at semaglutide exposures below what humans experience at therapeutic doses. In rat and rabbit studies cited in the FDA label, semaglutide caused embryo death, structural defects including skeletal malformations, and reduced fetal growth. These effects appeared at exposures as low as 0.1 times the maximum recommended human dose in some species.

This is the detail that matters most. Teratogen thresholds in animal studies are often set at multiples of the human dose, such as 10-fold or 50-fold, to give clinicians reassurance. Semaglutide does not clear that bar. Harm appeared well below human therapeutic exposure levels.

Human-to-Animal Extrapolation: Where the Evidence Gap Lives

A practical framework for interpreting semaglutide's reproductive risk sits on three tiers of evidence:

Tier 1 (direct human trial data): Does not exist. No randomized or prospective cohort study has evaluated semaglutide exposure during the first trimester in pregnant women. The SUSTAIN and PIONEER trial programs that established semaglutide's efficacy in type 2 diabetes excluded pregnant women entirely, as is standard for drug trials.

Tier 2 (post-marketing surveillance and registries): The FDA maintains a pregnancy exposure registry for Ozempic (1-800-727-6500). As of the most recent published data, case numbers remain too small to calculate reliable risk estimates. A 2024 analysis of GLP-1 receptor agonist pregnancies in a Danish registry found small numbers and could not rule out confounding by underlying diabetes or obesity.

Tier 3 (animal models): This is the only tier with systematic data. It points toward harm. Extrapolation from rodents and rabbits to humans is imperfect, but when two species show harm below clinical exposure levels, the risk signal is taken seriously by regulatory agencies.

Be honest with yourself about what this means: no one can tell you the exact risk from a brief first-trimester exposure. What clinicians can tell you is that the precautionary evidence is strong enough that no guideline body recommends continuing the drug in pregnancy.

What the FDA Label Says (and What It Does Not Say)

The semaglutide FDA prescribing information carries a pregnancy subsection that states: "Based on animal reproduction studies, there may be risks to the fetus from exposure to semaglutide during pregnancy." The label explicitly recommends discontinuation at least 2 months before a planned pregnancy.

The label does not assign a letter-grade pregnancy category (the A/B/C/D/X system was retired by the FDA in 2015 for new drugs). Under the current Pregnancy and Lactation Labeling Rule (PLLR), the label instead provides narrative risk summaries, which is what you see above.

ACOG's guidance on diabetes in pregnancy does not endorse GLP-1 receptor agonists for use during pregnancy, recommending insulin as the first-line pharmacologic treatment for both type 1 and type 2 diabetes in pregnant women, as insulin does not cross the placenta at clinically meaningful levels.

The Contraception Requirement You May Have Missed

If you are taking Ozempic and are not actively trying to conceive, you need reliable contraception. This is non-negotiable during treatment and for 2 months after your last dose.

Oral contraceptives deserve a specific note here. Semaglutide slows gastric emptying, which may reduce the peak absorption of oral contraceptive pills. A pharmacokinetic sub-study found that semaglutide reduced the peak plasma concentration of an oral contraceptive by approximately 20% compared to placebo. Whether this reduces contraceptive efficacy in practice is not definitively established, but many clinicians recommend using a non-oral method (IUD, patch, ring, implant, injectable) or adding a barrier method during Ozempic treatment, particularly during dose escalation.

Ozempic, PCOS, and the Ovulation-Restoration Problem

If you have polycystic ovary syndrome and you are prescribed Ozempic for metabolic reasons, you need to understand a specific fertility dynamic. PCOS is associated with anovulation, and many women with PCOS assume they cannot conceive easily. Semaglutide, through weight loss and insulin sensitization, may restore ovulation in women with PCOS who were previously not ovulating.

A 2022 randomized trial demonstrated that GLP-1 receptor agonist treatment in women with PCOS and obesity improved menstrual regularity and ovulation rates. Restored ovulation without reliable contraception means unplanned pregnancy is possible, and unplanned pregnancy on Ozempic is exactly the scenario the FDA label warns against.

If you have PCOS and are taking Ozempic with no intention of becoming pregnant right now, contraception is clinically necessary, not optional.

If You Are Trying to Conceive and Have PCOS

Ozempic is sometimes used off-label to improve metabolic parameters in women with PCOS before fertility treatment. The clinical strategy in this case is to use Ozempic to support weight loss and metabolic improvement, then stop the drug at least 2 months before attempting conception or starting assisted reproductive technology. Your reproductive endocrinologist and prescribing physician should coordinate this timeline explicitly.

ASRM guidance on obesity and infertility acknowledges that modest weight loss before fertility treatment improves outcomes in women with obesity-related anovulation, but does not specifically endorse continued GLP-1 use through a fertility cycle or into pregnancy.

Ozempic and Breastfeeding

Ozempic is not recommended during breastfeeding. The reason is not a confirmed harm signal but a data gap that warrants caution.

LactMed (NIH) notes that no published data exist on the excretion of semaglutide into human breast milk, its effects on the breastfed infant, or its effects on milk production. Because semaglutide is a large peptide molecule (molecular weight approximately 4,114 Da), it may not transfer into breast milk in significant quantities, and even if it does, gastrointestinal degradation would likely limit infant absorption. That mechanistic reasoning is reassuring but not sufficient to declare breastfeeding safe.

The FDA label states: "There are no data on the presence of semaglutide in human milk, the effects on the breastfed infant, or the effects on milk production." The label advises considering the developmental and health benefits of breastfeeding alongside the mother's clinical need for the drug and any potential adverse effects on the infant.

In practical terms: if you need semaglutide for glycemic control during the postpartum period, this is a conversation your endocrinologist and your infant's pediatrician should have together. For women using it off-label for weight loss, most clinicians would recommend waiting until breastfeeding is complete before restarting.

Postpartum Weight and the Timing Question

Postpartum weight retention is a real clinical issue. Women who gain significantly above recommended gestational weight targets face increased long-term cardiometabolic risk. The desire to restart Ozempic after delivery is understandable, but the data gap during lactation means the decision needs individualization rather than a blanket rule.

If you are not breastfeeding, the 2-month washout requirement that applied before conception does not apply in reverse. You can restart semaglutide after delivery if you are not breastfeeding and your prescriber agrees it is appropriate. Discuss timing with your OB-GYN, particularly in the context of postpartum glucose monitoring if you had gestational diabetes.

What to Use Instead: Managing Diabetes and Weight in Pregnancy

Insulin is the standard of care for pharmacologic management of both type 1 and type 2 diabetes in pregnancy. ACOG Practice Bulletin 201 recommends insulin as the preferred agent because of its established safety profile and the fact that it does not cross the placenta at therapeutic doses.

Metformin is sometimes used in pregnancy for type 2 diabetes or gestational diabetes, though it does cross the placenta and long-term offspring data remain under review. A 2020 Cochrane review found metformin acceptable in gestational diabetes with no clear increase in short-term neonatal harm, but the authors noted that long-term follow-up data for offspring are still being collected.

For weight management specifically, no pharmacologic agent is approved or recommended for use in pregnancy. Gestational weight gain targets from the National Academy of Medicine, which ACOG endorses, are based on pre-pregnancy BMI and provide a framework for healthy weight gain rather than active weight loss during pregnancy.

Nutrition and Lifestyle During Pregnancy With Obesity or Diabetes

Women with obesity or insulin resistance entering pregnancy benefit from working with a registered dietitian who specializes in perinatal nutrition. A dietitian can support appropriate gestational weight gain, glycemic management through carbohydrate distribution, and adequate micronutrient intake including folate, iron, and choline without the need for weight-loss pharmacology.

A 2015 trial in Lancet Diabetes and Endocrinology found that lifestyle intervention in pregnant women with obesity reduced excessive gestational weight gain but did not significantly reduce gestational diabetes incidence. The takeaway: diet and activity matter and are safe, but they have limits in pregnancy. Pharmacologic support waits until after delivery.

Who Should Stop Ozempic Before They See a Positive Test

You should discuss stopping Ozempic with your prescriber now if any of the following apply to you:

• You are in your reproductive years and not using reliable contraception
• You have PCOS and your cycles are becoming more regular since starting Ozempic (a sign of restored ovulation)
• You are planning to try to conceive within the next 6 months
• You are entering fertility treatment with a reproductive endocrinologist
• You are perimenopausal but have not had 12 consecutive months without a period (residual ovulatory cycles remain possible)

The 2-month minimum washout requires planning. If you want to try to conceive in June, your last injection should be in March at the latest.

Who Can Continue Ozempic Safely Right Now

Women who are not at risk for pregnancy, either because of confirmed menopause (12 or more consecutive months without menstruation), surgical sterilization, or reliable long-acting contraception, do not face the same urgency to stop. For these women, the pregnancy question is not active.

Post-menopausal women using semaglutide for cardiometabolic health or weight management face a different risk-benefit calculation entirely. The SELECT trial, which enrolled adults with established cardiovascular disease and overweight or obesity, demonstrated a 20% reduction in major adverse cardiovascular events with semaglutide 2.4 mg weekly versus placebo over a mean follow-up of 33 months. Post-menopausal women were well-represented in that trial, though sex-stratified outcomes were not the primary endpoint.

The Evidence Gap: What We Still Do Not Know

Women have been excluded from drug trials for decades, often under the rationale of protecting potential fetuses. The result is that nearly every conversation about drug safety in pregnancy and lactation involves extrapolation, animal data, and registry signals rather than direct human evidence. Semaglutide is no exception.

A 2019 analysis in JAMA Internal Medicine found that fewer than 5% of drug trials published between 2000 and 2018 enrolled pregnant participants. The semaglutide trials are consistent with that pattern. Every SUSTAIN and PIONEER phase 3 trial excluded pregnant or breastfeeding women.

What this means in practice: the absence of documented human harm from first-trimester semaglutide exposure does not mean the drug is safe in pregnancy. It means the data to evaluate safety do not exist. The animal signal, and the pharmacokinetic rationale, both point toward stopping the drug before conception.

The Motherisk program and similar teratogen information services consistently apply the principle that when animal data suggest harm and human data are absent, the precautionary recommendation is avoidance during pregnancy. That is the position reflected in the FDA label and in clinical guidelines from ACOG.

"Discontinue Ozempic at least 2 months before a planned pregnancy," the FDA prescribing label states directly. That instruction is the current standard of care.